Andrew H. Wei
0000-0002-7514-3298
Publication & Citation Trends
Most Cited Works
Publications
828 total
Olutasidenib for mutated IDH1 acute myeloid leukemia: final five-year results from the phase 2 pivotal cohort
Cited by 4
Semantic Scholar
A phase 2 study of olutasidenib in relapsed/refractory acute myeloid leukemia: Outcomes by number of prior treatment regimens.
Cited by 0
Semantic Scholar
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms.
Cited by 1
Semantic Scholar
Contemporary Approach to The Diagnosis and Classification of Myelodysplastic Neoplasms/Syndromes- Recommendations from The International Consortium for MDS (icMDS).
Cited by 8
Semantic Scholar
Time to Response and Overall Survival in Patients with mIDH1 Relapsed/Refractory Acute Myeloid Leukemia Treated with Olutasidenib
Cited by 1
Semantic Scholar
Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm
Cited by 4
Semantic Scholar
Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes.
Cited by 21
Semantic Scholar
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML) OA
Cited by 13
Semantic Scholar
Acute myeloid leukaemia
Cited by 362
OpenAlex
Research Topics
Acute Myeloid Leukemia Research
(477)
Ferroptosis and cancer prognosis
(159)
Cancer, Lipids, and Metabolism
(159)
RNA modifications and cancer
(147)
Chronic Myeloid Leukemia Treatments
(145)
Frequent Co-Authors
Affiliations
Goethe University Frankfurt
Poznan University of Medical Sciences
Universitat Autònoma de Barcelona
City Of Hope National Medical Center
The Royal Melbourne Hospital